Ascletis Announces U.S. IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19 ...Middle East

-- ASC11 is an in-house discovered oral small molecule drug candidate, targeting 3-chymotrypsin like protease (3CLpro) -- In antiviral cellular assays with infectious SARS-CoV-2, ASC11 demonstrated higher potency against SARS-CoV-2 than other 3CLpro inhibitors including Nirmatrelvir,...

Hence then, the article about ascletis announces u s ind filing of oral 3clpro inhibitor asc11 for covid 19 was published today ( Wednesday 02/11/2022 - 03:36 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Ascletis Announces U.S. IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19 )

Also on site :

• 12-year old Russian beats world chess champion
• Body recovered from Lake Natoma amid search for missing man
• ‘The Princess Bride’ Star Cary Elwes Shares Tribute to Rob Reiner: ‘From That Very First Meeting I Fell In Love With Him’